CL115,347, an Analogue of Prostaglandin E2
- 1 December 1985
- journal article
- research article
- Published by SAGE Publications in Angiology
- Vol. 36 (12) , 867-871
- https://doi.org/10.1177/000331978503601205
Abstract
The beneficial effects of intra-arterial or intravenous infusion of the prostanoid products of anachridonic acid, PGE and prostacyclin (PGI2) are well documented. More recently an analogue of PGE2, (CL 115,347, American Cynamid Co.) has become available. This substance is absorbed transdermally from a patch placed on the skin. In a placebo-controlled trial the vasodilatory effect of single incremental dosage, 500 mcg, 1000 mcg and 1500 mcg, was measured in a temperature-/humidity controlled laboratory in normal subjects and in patients with primary and secondary Raynaud's phenomenon. The optimal dosage proved to be 1000 mcg; the effect may last for 84 hours; higher dosage may be associated with a "steal" phenomenon.This publication has 5 references indexed in Scilit:
- Photoplethysmography of the Distal Pulp in the Assessment of the Vasospastic HandAngiology, 1985
- INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROMEThe Lancet, 1983
- EPOPROSTENOL (PROSTACYCLIN) AND SEVERE ARTERIAL DISEASEThe Lancet, 1983
- Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)British Journal of Dermatology, 1982
- SUCCESSFUL THERAPY OF ADVANCED ARTERIOSCLEROSIS OBLITERANS WITH PROSTACYCLINThe Lancet, 1979